Polaris Group AI Stock Analysis
Polaris Group (6550) AI Stock Analysis
Polaris Group
(TWSE:6550)
The score sits near the bottom of the range, driven primarily by severely weak financials: shrinking revenue, negative gross profit, five straight years of widening losses approaching NT$4 billion, and accelerating cash burn of roughly NT$2.4 billion from operations. Equity has eroded ~40% since 2022 while debt has multiplied more than six-fold, raising meaningful financing and dilution risk. Technicals reinforce the caution, with the stock trading far below all major moving averages and negative MACD momentum, although deeply oversold RSI and Stochastic readings leave room for a short-term bounce. Valuation provides no cushion given negative earnings and no dividend. This is a binary, pipeline-driven story where any re-rating depends on clinical and regulatory milestones rather than current financial performance.
Polaris Group (6550) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 6.39B
- Dividend Yield
- ―
- Average Volume (3M)
- 676.57K
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 0.39
- Revenue Growth
- 6.15%
- EPS Growth
- -13.99%
- Country
- TW
- Employees
- 83,293
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Polaris Group Business Overview & Revenue Model
Company Description
Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for th...
Polaris Group Financial Statement Overview
Summary
Polaris Group is a pre-commercial, clinical-stage biotech with no viable financial engine. Revenue fell ~43% to NT$40.6 million, gross profit is negative (-NT$270 million), and losses have widened for five consecutive years to nearly -NT$4.0 billion. Cash flow is the weakest link: operating cash flow of -NT$2.39 billion and free cash flow of -NT$3.19 billion, with burn exceeding the net loss, confirming losses are genuinely cash-consuming. The balance sheet offers the only partial support — NT$5.3 billion of equity and debt-to-equity near 0.44x — but equity has eroded ~40% since 2022 while debt multiplied more than six-fold, and ROE sits near -74%. This points to limited runway and a realistic prospect of further debt or dilutive equity raises.
Income Statement
7Very NegativeBalance Sheet
38NegativeCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.95M | 40.60M | 107.00M | 7.48M | 6.44M | 15.04M |
| Gross Profit | -420.06M | -270.32M | -76.92M | -137.90M | -141.86M | -150.62M |
| EBITDA | -2.06B | -2.50B | -2.17B | -1.41B | -990.13M | -570.97M |
| Net Income | -3.79B | -3.95B | -2.50B | -1.58B | -1.15B | -740.49M |
Balance Sheet | ||||||
| Total Assets | 7.38B | 8.17B | 9.09B | 9.10B | 9.22B | 7.82B |
| Cash, Cash Equivalents and Short-Term Investments | 2.30B | 2.74B | 3.12B | 4.95B | 7.38B | 6.33B |
| Total Debt | 2.36B | 2.35B | 1.88B | 1.20B | 382.62M | 436.75M |
| Total Liabilities | 2.84B | 2.87B | 2.32B | 1.46B | 545.18M | 608.23M |
| Stockholders Equity | 4.54B | 5.30B | 6.70B | 7.37B | 8.67B | 7.21B |
Cash Flow | ||||||
| Free Cash Flow | -2.67B | -3.19B | -3.69B | -1.59B | -1.10B | -743.60M |
| Operating Cash Flow | -2.11B | -2.39B | -2.03B | -1.26B | -1.03B | -539.26M |
| Investing Cash Flow | 79.45M | -659.66M | -1.63B | -3.24B | 199.68M | 1.02B |
| Financing Cash Flow | 2.39B | 2.96B | 1.85B | 919.16M | 1.48B | 5.35B |
Polaris Group Peers Comparison
Overall Rating
TW:415752Neutral
TW:417448Neutral- TW:655039Underperform
TW:649933Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4157 | 52Neutral | TWD 5.78B | 36.61 | ― | ― | 530.40% | ― |
| TW:4174 | 48Neutral | TWD 7.23B | -2.19 | ― | ― | -15.45% | 23.86% |
| TW:6550 | 39Underperform | TWD 6.55B | -1.57 | ― | ― | 6.15% | -13.99% |
| TW:6499 | 33Underperform | TWD 7.33B | -10.40 | ― | ― | 69.62% | 59.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6550 | Polaris Group | 14.10 | -46.15 | -76.60% | |
| TW:4157 | TaiGen Biopharmaceuticals Holdings Limited | 8.12 | -1.52 | -15.77% | |
| TW:4174 | OBI Pharma, Inc. | 55.00 | 6.60 | 13.64% | |
| TW:6499 | Medeon Biodesign, Inc. | 75.80 | -22.60 | -22.97% | |
| TW:6891 | Locus Cell Co., Ltd. | 37.00 | 7.50 | 25.42% | |
| TW:6976 | Acepodia, Inc. | 12.10 | -3.25 | -21.17% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026